Adtalem Global Education Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATGE research report →
Range $138 – $138
Price Chart
About the company
Adtalem Global Education Inc. is a global enterprise dedicated to delivering comprehensive workforce and educational solutions. Established in 1987 and headquartered in Chicago, Illinois, the company was formerly known as DeVry Education Group Inc.
- CEO
- Stephen W. Beard
- IPO
- 1991
- Employees
- 4,624
- HQ
- Chicago, IL, US
Get TickerSpark's AI analysis on ATGE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.87B
- P/E
- 14.22
- Fwd P/E
- 11.79
- PEG
- 0.73
- P/S
- 1.86
- P/B
- 2.68
- EV/EBITDA
- 8.92
- Div Yield
- 0.00%
- Gross Margin
- 57.39%
- Op Margin
- 19.86%
- Net Margin
- 12.84%
- ROE
- 18.33%
- ROIC
- 13.53%
Latest fiscal year · YoY change
- Revenue
- $1.95B+9.3%
- Gross Profit
- $1.12B+10.2%
- Op Income
- $383.38M
- Net Income
- $251.57M+6.1%
- EPS
- $7.18+14.5%
- OCF Growth
- +39.2%
- FCF Growth
- +36.6%
- 52W High
- $156.26
- 52W Low
- $86.26
- 50D MA
- $105.38
- 200D MA
- $120.07
- Beta
- 0.71
- RSI (14)
- 42
- Avg Volume
- 509.27K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Covista beat first-quarter expectations on broad-based enrollment growth, raised fiscal 27 guidance, and highlighted continued capital returns, while signaling some margin and cost pressure from new-campus investment and calendar shifts later in the year.· October 29, 2026
- Revenue rose 10.7% to $511.5 million; adjusted EBITDA increased 17.1% to $131.2 million; adjusted EPS increased 25.1% to $2.19.
- Total company enrollment grew 7.6% to nearly 105,000 students, marking the 13th consecutive quarter of enrollment growth.
- Management raised fiscal 27 guidance for both revenue and adjusted EPS, but kept a prudent full-year stance because of campus startup costs, a higher tax rate, and Walden’s calendar shift.
- Cash generation remained strong: trailing-12-month free cash flow was $355 million, net leverage was 0.5x, and the company repurchased $84 million of stock in the quarter.
- CFO Robert Phelan said he will retire after a successor is named, creating a CFO transition in progress.
First-quarter revenue increased 10.7% to $511.5 million. Adjusted EBITDA was $131.2 million, up 17.1%, and adjusted EBITDA margin was 25.6%, up 1.4 percentage points. Adjusted net income rose 16.8% to $75.8 million, and adjusted EPS was $2.19, up 25.1%. By segment, Chamberlain revenue grew 7.4% to $192.4 million and adjusted EBITDA rose 7.1% to $37.6 million; Walden revenue rose 14.1% to $216.7 million and adjusted EBITDA rose 16.1% to $71.9 million; medical and veterinary revenue rose 10% to $102.5 million and adjusted EBITDA rose 27.9% to $27.4 million. For fiscal 27, Covista now expects revenue of $2.06 billion to $2.095 billion and adjusted EPS of $9.00 to $9.20, versus prior guidance of $2.05 billion to $2.09 billion and $8.90 to $9.15. Management still expects full-year EBITDA margin expansion of 0 to 0.5 percentage points, capex above fiscal 26 levels, and a higher effective tax rate.
Stephen Beard framed the quarter as evidence that the company is “running ahead” of fiscal 27 guidance and said the business is benefiting from durable demand in health care education. He emphasized the “purpose at scale” strategy: adding campuses and programs, deepening employer partnerships, and investing in technology including an AI-powered classroom and LLM-search optimization. His tone was confident but measured, repeatedly noting that the company is investing ahead of growth and will update guidance as visibility improves.
Robert Phelan said the quarter showed the operating model working at scale, with revenue up 10.7%, adjusted EBITDA up 17.1%, and margins expanding 1.4 percentage points. He highlighted trailing-12-month free cash flow of $355 million, cash and equivalents of $222 million, net leverage of 0.5x, and a $510 million term-loan repricing that cut the spread by 25 basis points to SOFR plus 2%. He also noted $84 million of share repurchases in the quarter, about 660,000 shares at an average price of $127.63, and said the company still has $578 million remaining under its $750 million authorization.
Analysts pressed management on whether federal loan-category confusion affected enrollments, especially in nursing and medical/veterinary programs. Beard said he did not think nursing was impacted, and reiterated that the only notable dynamics in med-vet were some pull-forward from students trying to get ahead of loan changes plus some temporary hesitancy around financing the full journey. Questions also focused on Chamberlain’s lower-than-expected enrollment growth and the lighter lift in full-year guidance despite the quarter’s beat; Beard said the company expects Chamberlain to improve as persistence efforts and RN-to-BSN pricing actions take hold, while the guidance remains prudent because of Walden’s calendar shift, campus startup costs, and tax-rate pressure. Analysts also asked about AI/search effects and working capital; management said LLM search has not created real headwinds so far and receivables were higher largely in line with revenue growth and academic-session timing.
The bull case from this call is that demand for health care education remains strong, with enrollment growth across all three segments and management saying there is no reduction in demand from employers or students. Covista also showed strong cash conversion, low leverage, and continued buybacks, giving it room to fund expansion while returning capital. Management sounded confident that Chamberlain, Walden, and med-vet all have multiple growth levers still in motion.
The main risks discussed were self-inflicted investment drag and timing effects: Chamberlain is incurring startup costs ahead of enrollment, Walden’s academic-calendar shift will make second-quarter comparisons look weak, and management expects a higher tax rate this year. Chamberlain’s total enrollment growth of 1.3% was described as slightly below expectations, with softness in returning students and RN-to-BSN prompting corrective actions. There is also a CFO transition underway, and management acknowledged ongoing monitoring of AI-search behavior, loan-policy effects, and consumer financing hesitancy in medical education.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.7%
- Shares Outstanding
- 36.33M
- Float Shares
- 33.67M
of shares held by institutions
365 13F filers
Buy/sell ratio 1.05. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.35M | ▲ 10.54K |
| Northern Trust Corp | 434.99K | ▲ 20.66K |
| Aqr Capital Management LLC | 271.95K | ▼ 10.22K |
| Two Sigma Investments, LP | 259.44K | ▼ 235.09K |
| Allianz Asset Management Gmbh | 198.98K | ▼ 33.33K |
| Two Sigma Advisers, LP | 192.10K | ▲ 82.70K |
| Bank Of America Corp | 176.31K | ▼ 51.83K |
| Goldman Sachs Group Inc | 163.15K | ▼ 182.69K |
| Algert Global LLC | 155.01K | ▼ 296 |
| Corient Private Wealth LP | 137.90K | ▲ 1.92K |
| Prudential Financial Inc | 127.64K | ▼ 2.75K |
| Jupiter Topco LLC | 108.25K | ▲ 108.25K |
Held by 26 ETFs
Biggest fund positions in ATGE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 10, 25 | Beard, Stephen W. | other | 5,332 |
| Nov 12, 25 | WARDELL LISA W | other | 1,445 |
| Nov 13, 25 | WARDELL LISA W | other | 645 |
| Nov 12, 25 | Vandenbosch Betty M. | other | 1,445 |
| Nov 13, 25 | Vandenbosch Betty M. | other | 421 |
| Nov 12, 25 | Trent Evan | other | 1,673 |
| Nov 13, 25 | Trent Evan | other | 355 |
| Nov 12, 25 | Phelan Robert J. | other | 4,259 |
| Nov 13, 25 | Phelan Robert J. | other | 623 |
| Nov 12, 25 | Phelan Kenneth J | other | 1,445 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATGE coverage
Recent articles, reports, and earnings notes.
No research on ATGE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATGE report →Algert Global LLC Cuts Stock Position in Adtalem Global Education Inc. $ATGE
defenseworld.net · Mar 15
CreativeOne Wealth LLC Invests $862,000 in Adtalem Global Education Inc. $ATGE
defenseworld.net · Mar 12
Adtalem Global Education Inc. $ATGE Position Reduced by Citigroup Inc.
defenseworld.net · Mar 8
Covista Unveils Strategic Plan for Continued Momentum and Long-Term Value Creation at Investor Day
businesswire.com · Feb 24
Ross University School of Medicine Welcomes New Dean
businesswire.com · Feb 17
Why Adtalem Global Education (ATGE) is a Top Value Stock for the Long-Term
zacks.com · Feb 16
Why This $14 Million Bet on Adtalem Global Stock Could Signal a Healthcare Education Pivot
fool.com · Feb 13
John Rogers' Strategic Moves: Sphere Entertainment Co Sees Significant Reduction
gurufocus.com · Feb 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.